Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M305078200 on June 27, 2003

J. Biol. Chem., Vol. 278, Issue 37, 35710-35717, September 12, 2003
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
278/37/35710    most recent
M305078200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ganesan, L. P.
Right arrow Articles by Tridandapani, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ganesan, L. P.
Right arrow Articles by Tridandapani, S.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

The Protein-tyrosine Phosphatase SHP-1 Associates with the Phosphorylated Immunoreceptor Tyrosine-based Activation Motif of Fc{gamma}RIIa to Modulate Signaling Events in Myeloid Cells*

Latha P. Ganesan, Huiqing Fang, Clay B. Marsh and Susheela Tridandapani {ddagger}

From the Department of Internal Medicine, Division of Pulmonary and Critical Care Medicine, The Dorothy M. Davis Heart and Lung Institute, and Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio 43210

Received for publication, May 14, 2003 , and in revised form, June 24, 2003.


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Fc{gamma}RIIa is a low affinity IgG receptor uniquely expressed in human cells that promotes phagocytosis of immune complexes and induces inflammatory cytokine gene transcription. Recent studies have revealed that phagocytosis initiated by Fc{gamma}RIIa is tightly controlled by the inositol phosphatase SHIP-1, and the protein-tyrosine phosphatase SHP-1. Whereas the molecular nature of SHIP-1 involvement with Fc{gamma}RIIa has been well studied, it is not clear how SHP-1 is activated by Fc{gamma}RIIa to mediate its regulatory effect. Here we report that Fc{gamma}RIIa clustering induces SHP-1 phosphatase activity in THP-1 cells. Using synthetic phosphopeptides, and stable transfectants expressing immunoreceptor tyrosine-based activation motif (ITAM) tyrosine mutants of Fc{gamma}RIIa, we demonstrate that SHP-1 associates with the phosphorylated amino-terminal ITAM tyrosine of Fc{gamma}RIIa, whereas the tyrosine kinase Syk associates with the carboxyl-terminal ITAM tyrosine. Association of SHP-1 with Fc{gamma}RIIa ITAM appears to suppress total cellular tyrosine phosphorylation. Furthermore, Fc{gamma}RIIa clustering results in the association of SHP-1 with key signaling molecules such as Syk, p85 subunit of PtdIns 3-kinase, and p62dok, suggesting that these molecules may be substrates of SHP-1 in this system. Finally, overexpression of wild-type SHP-1 but not catalytically deficient SHP-1 led to a down-regulation of NF{kappa}B-dependent gene transcription in THP-1 cells activated by clustering Fc{gamma}RIIa.


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
IgG receptors (Fc{gamma}R) on monocytes and macrophages mediate immune complex clearance by a process termed phagocytosis (1). At least four classes of Fc{gamma}R are expressed on monocytes and macrophages (2); Fc{gamma}RI, Fc{gamma}RIIa, and Fc{gamma}RIIIa are all activating receptors that are associated with immunoreceptor tyrosine-based activation motif (ITAM).1 In contrast, Fc{gamma}RIIb is an inhibitory receptor that is associated with an immunoreceptor tyrosine-based inhibition motif (ITIM). Of these receptors Fc{gamma}RIIa is uniquely expressed in human cells and is the only ITAM-associated receptor that bears the ITAM within its cytoplasmic tail (3, 4). Of the ITAMs identified to date, the ITAM of Fc{gamma}RIIa has the longest spacer region between the two YXXL motifs that together make the ITAM. The functional significance of this extended spacer is not fully understood. In addition, Fc{gamma}RIIa is the most widely expressed Fc{gamma}R in the human hematopoetic system.

Clustering of Fc{gamma}R by immune complexes initiates a cascade of signaling events, the first of which is the activation of the Src family of tyrosine kinases that phosphorylate the ITAMs of Fc{gamma}R (5, 6). The phosphorylated ITAMs serve as docking sites for SH2 domain-containing cytosolic enzymes and enzyme-adapter complexes including the tyrosine kinase Syk and the p85 adapter subunit of PtdIns 3-kinase (7). Association of Syk with the phosphorylated ITAM activates the enzyme resulting in autophosphorylation of Syk and tyrosine phosphorylation of multiple cytosolic proteins (8, 9). Likewise, association of p85 with the ITAM delivers PtdIns 3-kinase to the proximity of its lipid substrates in the membrane, resulting in the generation of 3'-phosphorylated inositol lipids that activate PH domain-containing enzymes to promote cytoskeletal changes required for the phagocytic process (10). Inactivation of either Syk or PtdIns 3-kinase has been shown to completely abrogate Fc{gamma}R-mediated phagocytosis (11–14).

Phagocytosis is a complex process that is accompanied by the generation of reactive oxygen radicals and the production of inflammatory cytokines, which results in tissue damage. Therefore the phagocytic process is subject to a tight regulation. In this regard, several mechanisms have been proposed including the expression and function of the inhibitory receptor Fc{gamma}RIIb (15–17), the function of intracellular inhibitory phosphatases such as the inositol phosphatases SHIP-1 (18–20) and SHIP-2 (21), and the protein-tyrosine phosphatase SHP-1 (22). Recent studies have revealed that the inositol phosphatases SHIP-1 and SHIP-2 not only work through the ITIM of Fc{gamma}RIIb, but are also capable of associating with the ITAMs of Fc{gamma}R to modulate activation events, thus providing an additional level of complexity to the regulation of phagocytosis (19, 20, 23). Whereas the molecular details of ITAM-mediated activation of the SHIP proteins is well studied, it is not known how SHP-1 is activated by ITAM-bearing receptors.

SHP-1 is a cytosolic tyrosine phosphatase that negatively regulates immune receptor signaling and growth factor signaling (24, 25). SHP-1 is predominantly expressed in hematopoetic cells and contains two NH2-terminal located SH2 domains, a central phosphatase domain and two tyrosine phosphorylation sites in the COOH-terminal region. The enzyme is regulated by intramolecular interactions such that the NH2-terminal SH2 domain folds over the catalytic domain to inactivate the enzyme (26–28). Deletion of the NH2-terminal SH2 domain, or engagement of the SH2 domains with cognate phosphopeptides has been shown to activate the phosphatase. Enzyme activity of SHP-1 is further enhanced by phosphorylation of tyrosines (Tyr536 and Tyr564) in the COOH-terminal region (29). The significance of the regulatory role of SHP-1 in the hematopoetic system is best exemplified in mice homozygous for motheaten (me/me) or motheaten viable (mev/mev) mutations (30–32). The me/me mice do not express any SHP-1 protein, whereas the mev/mev mice express inactive splice variants of SHP-1. Both of these mutations result in multiple hematopoetic defects including elevated levels of autoantibodies and chronic inflammation resulting in early mortality. In a recent study, Durden and colleagues (22) have demonstrated that SHP-1 down-regulates Fc{gamma}R-mediated phagocytosis in the J774A.1 mouse macrophage cell line.

In this study we have analyzed the molecular details of SHP-1 activation by the human Fc{gamma}RIIa and the functional consequence of this activation. We report that SHP-1 phosphatase activity is induced upon Fc{gamma}RIIa clustering in THP-1 human monocytic cells. Fc{gamma}RIIa clustering results in membrane translocation of SHP-1 and association of SHP-1 with the phosphorylated ITAM of Fc{gamma}RIIa. Co-precipitation experiments in cells transfected with ITAM tyrosine mutants of Fc{gamma}RIIa revealed that SHP-1 associates with the NH2-terminal ITAM tyrosine, whereas Syk associates with the COOH-terminal ITAM tyrosine. Previous studies using substrate-trapping mutants of SHP-1 have demonstrated that SHP-1 associates with and dephosphorylates Syk, p85, and p62dok in other cell systems (33–35). Likewise, our current studies demonstrate association of SHP-1 with the above molecules upon Fc{gamma}RIIa clustering suggesting that SHP-1 may dephosphorylate these molecules to down-regulate related signaling pathways. Consistent with this notion, analysis of functional consequence of SHP-1 phosphatase activity during Fc{gamma}RIIa signaling demonstrated that overexpression of wild-type SHP-1 but not catalytically deficient SHP-1 down-regulates NF{kappa}B-dependent gene transcription following Fc{gamma}RIIa signaling. Taken together these results suggest that signaling events initiated by the ITAM of Fc{gamma}RIIa are a composite of both positive and negative regulatory enzyme activation.


   MATERIALS AND METHODS
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
RESULTS
 DISCUSSION
 REFERENCES
 
Cells, Antibodies, and Reagents—THP-1 cells were obtained from ATCC and cultured in RPMI supplemented with 10% fetal bovine serum. P388D1 transfectants expressing human Fc{gamma}RIIa were a generous gift from Dr. J. C. Edberg (University of Alabama) (36). COS-7 cells were cultured in Dulbecco's modified Eagle's medium with 10% fetal bovine serum. Anti-Fc{gamma}RIIa antibody IV.3 was obtained from Medarex (Annandale, NJ). Rabbit polyclonal SHP-1, p85, Syk antibodies, and mouse monoclonal anti-phosphotyrosine antibody and phosphatase assay kits were purchased from Upstate Biotechnology (Charlottesville, VA).

Immunoprecipitation and Western Blotting—THP-1 cells and transfected P388D1 cells were activated by clustering Fc{gamma}RIIa with F(ab')2 fragments of monoclonal antibody IV.3 and goat F(ab')2 anti-mouse Ig secondary antibody. Resting and activated cells were lysed in TN1 buffer (50 mM Tris, pH 8.0, 10 mM EDTA, 10 mM Na4P2O7, 10 mM NaF, 1% Triton X-100, 125 mM NaCl, 10 mM Na3VO4, 10 µg/ml each aprotinin and leupeptin), and postnuclear lysates were incubated overnight with the antibody of interest and protein G-agarose beads (Invitrogen) or goat anti-mouse Ig covalently linked to Sepharose, depending on the antibody. Immunoprecipitations with control antibodies were performed in lysates of cells stimulated for 3 min. Immune complexes bound to beads were washed in TN1 and boiled in SDS sample buffer (60 mM Tris, pH 6.8. 2.3% SDS, 10% glycerol, 0.01% bromphenol blue, and 1% 2-mercaptoethanol) for 5 min. Proteins were separated by SDS-PAGE, transferred to nitrocellulose filters, probed with the antibody of interest, and developed by enhanced chemiluminescence.

Analysis of Fc{gamma}RIIa Expression by Flow Cytometry—P388D1 transfectants were tested for expression of Fc{gamma}RIIa by incubating with Fab fragments of anti-Fc{gamma}RIIa monoclonal antibody IV.3, at a concentration of 10 µg/ml for 30 min at 4 °C. The cells were washed and incubated with fluorescein isothiocyanate-labeled goat F(ab')2 anti-mouse Ig secondary antibody for 30 min at 4 °C. Cells were subsequently washed, fixed in 1% paraformaldehyde, and analyzed by flow cytometry on an Elite EPICS fluorescence-activated cell sorter (Coulter, Hialeah, FL). Data from 10,000 cells per condition were recorded to yield the percentage of cells expressing receptors.

Phosphatase Assays—Phosphatase assays were performed as described previously (37), with slight modifications. To measure phosphatase activity associated with SHP-1, Fc{gamma}RIIa, Syk, p85, p62dok, and Erk, these proteins were immunoprecipitated from resting and activated (Fc{gamma}RIIa clustering) THP-1 cells. Immunoprecipitations with control antibodies were done in lysates of cells stimulated for 7 min. The immunoprecipitates were washed six times in wash buffer (10 mM Tris, pH 7.4), and subsequently incubated with tyrosine phosphopeptide substrate (RRLIEDAEpYAARG) (Upstate Biotechnology) in 10 mM Tris, pH 7.4, for 30 min. Reaction was stopped with 100 µl of malachite green solution, incubated for a further 15 min, and the absorbance was measured at 630 nm. All assays were performed at least three times and the values obtained were plotted as mean ± S.D.

Transfection of THP-1 Cells and Luciferase Assays—For analysis of SHP-1 influence on NF{kappa}B transcriptional activity, THP-1 cells were transfected by electroporation (310 V, 950 µF; Bio-Rad Gene Pulser II) with 5 µg of wild-type SHP-1 or catalytically deficient (D419A) SHP-1 (a kind gift from Dr. R. Siraganian) (38), 1 µg of NF{kappa}B-luc plasmid, and 0.5 µg of pEGFP to normalize for transfection efficiency. Transfectants were harvested 24 h later, activated by clustering Fc{gamma}RIIa by methods described above for 6 h at 37 °C. The cells were lysed in 100 µl of cell culture lysis reagent (Promega). Luciferase activity was measured using the Promega luciferase assay reagent. Data are represented as graphs indicating the % increase in NF{kappa}B activity in cells activated by clustering Fc{gamma}RIIa over those that were not activated. Data points are expressed as mean ± S.D. of three independent experiments. Statistical analysis was performed by Student's t test.

Transfection of COS-7 Cells—COS-7 cells were transfected as previously described (39). Briefly, cells were grown on culture dishes until they were 60–70% confluent. Plasmids encoding wild-type SHP-1 and D419A SHP-1 were mixed with LipofectAMINE 2000 reagent (Invitrogen). The DNA mixture was added to cells in serum-free Dulbecco's modified Eagle's medium and incubated for 3 h at 37 °C in a CO2 incubator. The media was then replaced by Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum. The cells were harvested 24 h later and analyzed for expression of the transfected cDNAs by Western blotting whole cell lysates and SHP-1 immunoprecipitates from the transfectants were assessed for phosphatase activity as described above.

GFP-SHP-1 Construct—Wild-type SHP-1 cDNA in pSVL vector was obtained from Dr. R. Siraganian, and subcloned into pEGFP vector (Clontech) using the Xho and XbaI sites. Expression of GFP-SHP-1 was first confirmed by transfecting COS-7 fibroblasts with either empty EGFP vector or GFP-SHP-1 constructs, and subsequent Western blotting with anti-SHP-1 antibody.

Transfection of P388D1 Cells and Confocal Microscopy—P388D1 cells stably expressing human Fc{gamma}RIIa were transfected with GFP-SHP-1 plasmids using LipofectAMINE, as described above for COS-7 cells. Cells were harvested 24 h post-transfection, serum starved, and stimulated by clustering Fc{gamma}RIIa for 5 min. Resting and activated cells were fixed in 1% paraformaldehyde, cytospun onto glass slides, and stained with Hoechst nuclear stain. Slides were then mounted using mounting media (Molecular Probes) and analyzed by confocal microscopy using a Zeiss LSM510 multiphoton confocal microscope.


   RESULTS
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
DISCUSSION
 REFERENCES
 
SHP-1 Is Activated by Fc{gamma}RIIa Clustering—To assess whether SHP-1 is activated by Fc{gamma}RIIa, THP-1 cells were stimulated by clustering Fc{gamma}RIIa with Fab fragments of the receptor-specific monoclonal antibody IV.3, followed by secondary cross-linking with goat F(ab')2 fragments of anti-mouse Ig antibody. SHP-1 was immunoprecipitated from resting and activated cells and analyzed first, for phosphatase activity (Fig. 1A) and second, for tyrosine phosphorylation by Western blotting (Fig. 1B). The use of Fab/F(ab')2 fragments of the clustering antibodies precludes the engagement of other Fc{gamma}R present on the THP-1 cells by IgG ligand interaction ensuring that the resultant signals are emanating from Fc{gamma}RIIa alone. In Fig. 1A, SHP-1 phosphatase activity was measured in THP-1 cells activated for the various time points indicated in the figure. Results indicate that SHP-1 phosphatase activity is induced by Fc{gamma}RIIa clustering and the activity peaks around 7 min post-stimulation. Previous studies have indicated that the enzyme activity of SHP-1 is enhanced upon tyrosine phosphorylation of SHP-1 (29). The results shown in Fig. 1B demonstrate that SHP-1 is tyrosine-phosphorylated upon Fc{gamma}RIIa clustering. A reprobe of the same membrane with anti-SHP-1 antibody in the lower panel indicates equal loading of SHP-1 in all lanes. The last lane marked "C" is a control immunoprecipitate with normal rabbit IgG.



View larger version (30K):
[in this window]
[in a new window]
  		FIG. 1.
SHP-1 is activated by Fc{gamma}RIIa clustering in THP-1 cells. A, THP-1 cells were activated by clustering Fc{gamma}RIIa for the time points indicated in the figure. SHP-1 was immunoprecipitated from resting and activated samples, and assayed for phosphatase activity by measuring the release of phosphate from a phosphopeptide substrate. Values plotted in the graph were obtained by subtracting the values in resting samples. The graph represents the mean ± S.D. of values from three independent experiments. B, SHP-1 immunoprecipitates from resting and activated THP-1 cells were analyzed by Western blotting with anti-phosphotyrosine antibody (upper panel). The lower panel is a reprobe of the same membrane with anti-SHP-1 antibody. These results are representative of three independent experiments. C, THP-1 cells were subjected to immunoprecipitation with Fab fragments of Fc{gamma}RIIa-specific monoclonal antibody IV.3, intact IV.3 antibody, and pan-Fc{gamma}RII antibodies KB61 and AT10. The ability of the antibodies to immunoprecipitate Fc{gamma}RIIb was tested by Western blotting with Fc{gamma}RIIb-specific antibody 163 (upper panel). Parallel samples were analyzed by Western blotting with Fc{gamma}RIIa-specific antibody 260. D, P388D1 mouse macrophages stably expressing human Fc{gamma}RIIa were transiently transfected with GFP-SHP-1, activated by clustering Fc{gamma}RIIa for 5 min, and analyzed by confocal microscopy.

 

To further confirm that the clustering antibodies used do not engage other Fc{gamma}R expressed on THP-1 cells, specifically Fc{gamma}RIIb, which bears a high level homology with Fc{gamma}RIIa in the extracellular domain, binding of Fab fragments of monoclonal antibody IV.3 to Fc{gamma}RIIb was analyzed. For this THP-1 cells were subjected to immunoprecipitation with Fab fragments of IV.3, intact IV.3 IgG, and two pan-Fc{gamma}RII antibodies KB61 and AT10. The immunoprecipitates were probed with rabbit polyclonal antibodies specific for either Fc{gamma}RIIb (Fig. 1C, upper panel) or Fc{gamma}RIIa (Fig. 1C, lower panel). Results indicate that whereas all four antibodies used are able to immunoprecipitate Fc{gamma}RIIa, Fab fragments of IV.3 are unable to bind Fc{gamma}RIIb. The pan-Fc{gamma}RII antibodies KB61 and AT10 bound Fc{gamma}RIIb as expected. Intact IV.3 IgG was also able to precipitate some Fc{gamma}RIIb presumably by ligand interaction, as we have previously reported. Taken together these results demonstrate that SHP-1 is activated by the ITAM-bearing Fc{gamma}RIIa in THP-1 cells, without the involvement of Fc{gamma}RIIb.

SHP-1 Translocates to the Membrane upon Fc{gamma}RIIa Clustering—To test whether Fc{gamma}RIIa clustering resulted in membrane translocation of SHP-1, GFP-SHP-1 constructs were generated and transiently transfected into P388D1 mouse macrophage cells stably expressing human Fc{gamma}RIIa. Cells were stimulated for 5 min by clustering Fc{gamma}RIIa and analyzed by confocal microscopy. Results indicated that SHP-1 is distributed in the cytoplasm in resting cells and translocates to the membrane in cells activated by clustering Fc{gamma}RIIa (Fig. 1D). In parallel samples transfected with EGFP alone, no movement of GFP was observed in activated cells compared with resting cells (data not shown).

SHP-1 Co-immunoprecipitates with Fc{gamma}RIIa—We next assessed whether SHP-1 associates with Fc{gamma}RIIa to become activated. Here, THP-1 cells were activated by clustering Fc{gamma}RIIa by the methods described above. SHP-1 was immunoprecipitated from resting and activated cells, and analyzed for association with Fc{gamma}RIIa by Western blotting with the Fc{gamma}RIIa-specific antibody 260. Results indicated that SHP-1 associates with Fc{gamma}RIIa upon activation (Fig. 2A, upper panel). No association was detectable in resting cells. The same membrane was reprobed with anti-SHP-1 antibody to ensure equivalent loading of SHP-1 in all lanes (lower panel).



View larger version (33K):
[in this window]
[in a new window]
  		FIG. 2.
SHP-1 co-immunoprecipitates with Fc{gamma}RIIa. THP-1 cells were activated for the time points indicated in the figure by clustering Fc{gamma}RIIa. A, SHP-1 was immunoprecipitated from resting and activated cells and analyzed by Western blotting with anti-Fc{gamma}RIIa antibody (260) (upper panel). The membrane was reprobed with anti-SHP-1 antibody to demonstrate equal loading in all lanes (lower panel). The last lane is a control immunoprecipitation with normal rabbit IgG, in cells stimulated for 3 min. B, Fc{gamma}RIIa immunoprecipitates from resting and activated THP-1 cells were analyzed for the presence of phosphatase activity. These data represent mean ± S.D. of three independent experiments.

 

As a second approach to confirm association of SHP-1 with Fc{gamma}RIIa, the receptors were immunoprecipitated from resting and activated THP-1 cells and subjected to a phosphatase assay with a phosphopeptide substrate. The amount of free phosphate released was detected by the addition of malachite green. Results are expressed as picomole of phosphate released by immunoprecipitates from activated cells after subtracting the values obtained from immunoprecipitates from resting cells (Fig. 2B). Control immunoprecipitates consistently showed values equal to or lower than resting cell immunoprecipitates. Together these experiments demonstrate that SHP-1 associates with Fc{gamma}RIIa following receptor clustering.

NH2-terminal ITAM Tyrosine of Fc{gamma}RIIa Is Necessary for Association with SHP-1—To examine which of the two ITAM tyrosines of Fc{gamma}RIIa were involved in the association with SHP-1, we used two experimental models. First, synthetic biotinylated peptides derived from the ITAM of Fc{gamma}RIIa, which were either non-phosphorylated (P1), or singly phosphorylated on either the NH2-terminal ITAM tyrosine (P2) or the COOH-terminal ITAM tyrosine (P3), were applied to THP-1 lysates and the peptide-bound material was analyzed for the presence of SHP-1 by Western blotting. The results shown in Fig. 3A, upper panel, indicate that the phosphorylated NH2-terminal ITAM tyrosine, but not the COOH-terminal tyrosine, efficiently bound SHP-1. SHP-1 did not associate with the non-phosphorylated peptide (lane 1). In contrast, parallel experiments analyzing the binding properties of the peptides demonstrated that the peptide phosphorylated on the COOH-terminal ITAM tyrosine is functional and is able to associate with Syk (Fig. 3A, middle panel) and p85 (Fig. 3A, lower panel). These latter findings are consistent with earlier reports demonstrating that the COOH-terminal ITAM tyrosine of Fc{gamma}RIIa is sufficient for association with Syk (40), and that p85 associates with both NH2- and COOH-terminal ITAM tyrosines of Fc{gamma}RIIa (6, 41).



View larger version (55K):
[in this window]
[in a new window]
  		FIG. 3.
SHP-1 associates with phosphorylated NH2-terminal ITAM tyrosine of Fc{gamma}RIIa. A, non-phosphorylated (P1) and singly phosphorylated (P2 and P3) synthetic, biotinylated peptides derived from Fc{gamma}RIIa were applied to THP-1 lysates, and the peptide-bound material was analyzed for the presence of SHP-1 by Western blotting with anti-SHP-1 antibody (upper panel). Parallel samples were probed with anti-Syk antibody (middle panel) and with anti-p85 antibody (lower panel). These data are representative of five independent experiments. B, stable P388D1 transfectants, expressing either the NH2-terminal ITAM tyrosine mutant (Y252F) or the COOH-terminal ITAM tyrosine mutant (Y268F) of human Fc{gamma}RIIa, were activated by clustering Fc{gamma}RIIa receptors. Fc{gamma}RIIa was immunoprecipitated from resting and activated cells and analyzed for association with SHP-1 by Western blotting with anti-SHP-1 antibody (upper panel). The same membrane was stripped and reprobed with anti-Syk antibody (middle panel), and with anti-Fc{gamma}RIIa antibody (lower panel).

 

Because the above experiments were performed with synthetic peptides, we next asked whether the native Fc{gamma}RIIa receptor would likewise demonstrate the differential ITAM tyrosine requirement for association with SHP-1 and Syk. For these experiments we used P388D1 mouse macrophage transfectants stably expressing single ITAM tyrosine mutants of human Fc{gamma}RIIa. The P388D1 transfectants were activated by clustering Fc{gamma}RIIa, the receptors were immunoprecipitated from resting and activated cells and analyzed by Western blotting for co-precipitating SHP-1 (Fig. 3B, upper panel) or Syk (Fig. 3B, lower panel). Results indicated that SHP-1 failed to associate with Fc{gamma}RIIa when the NH2-terminal ITAM tyrosine was mutated to phenylalanine (Y252F). However, the Y252F receptor displayed efficient binding to Syk. These results are consistent with the above peptide binding experiments.

To assess the signaling outcome of the ITAM tyrosine mutations, we compared the ability of these mutated receptors versus the wild-type receptor to induce signaling. For this we first ensured that the transfected receptors were expressed to comparable levels by flow cytometry (Fig. 4A). The transfected cells were stimulated by clustering Fc{gamma}RIIa. Fc{gamma}RIIa was immunoprecipitated from resting and activated cells and analyzed for tyrosine phosphorylation. Results indicated that all three receptors are capable of being tyrosine phosphorylated (Fig. 4B, upper panel). As might be expected the single ITAM tyrosine mutants displayed lower phosphorylation levels than the wild-type receptor. A reprobe of the membrane demonstrated equivalent receptor expression in the transfectants (Fig. 4B, lower panel). The reduced signal seen with anti-Fc{gamma}RIIa antibody in the activated lane is because of the fact that the anti-Fc{gamma}RIIa blotting antibody often displays lower efficiency of detection of the phosphorylated Fc{gamma}RIIa in a reprobe. We, and others, have previously reported this property of the anti-Fc{gamma}RIIa blotting antibody (19, 42).



View larger version (36K):
[in this window]
[in a new window]
  		FIG. 4.
Mutation of Fc{gamma}RIIa NH2-terminal ITAM tyrosine results in enhanced tyrosine phosphorylation of signaling proteins. A, P388D1 mouse macrophage cell lines stably transfected to express wild-type human Fc{gamma}RIIa or the ITAM tyrosine mutants were analyzed by flow cytometry for expression of the transfected receptor. B, P388D1 transfectants were activated by clustering Fc{gamma}RIIa for 5 min, Fc{gamma}RIIa was immunoprecipitated and assessed for tyrosine phosphorylation by Western blotting with anti-phosphotyrosine antibody (upper panel). The same membrane was reprobed with anti-Fc{gamma}RIIa antibody (260) to ensure the presence of receptor in all transfectants (lower panel). C, whole cell lysates (WCL) from an equal number of resting and activated P388D1 transfectants were analyzed for overall cellular phosphorylation by Western blotting with anti-phosphotyrosine antibody. These data are representative of three independent experiments.

 

We next analyzed total cellular tyrosine phosphorylation in the transfectants stimulated by Fc{gamma}RIIa clustering (Fig. 4C). Results indicated that, clustering of the NH2-terminal ITAM tyrosine mutant leads to enhanced overall cellular tyrosine phosphorylation in comparison to clustering of the wild-type receptor (lane 4 versus lane 1). In contrast, mutation of the COOH-terminal ITAM tyrosine completely abrogated overall cellular phosphorylation. These observations are consistent with the notion that SHP-1 associates with the NH2-terminal ITAM tyrosine to down-modulate tyrosine phosphorylation events, and that Syk associates with the COOH-terminal ITAM tyrosine to become activated and lead to the phosphorylation of signaling proteins in the cell.

SHP-1 Associates with p85, Syk, and p62dok during Fc{gamma}RIIa Signaling—The activation of SHP-1 during Fc{gamma}RIIa signaling suggests that SHP-1 causes dephosphorylation of tyrosine-phosphorylated proteins. Numerous previous studies have identified the association of SHP-1 with tyrosine-phosphorylated signaling molecules, the subsequent dephosphorylation of these molecules, and down-regulation of the related signaling pathways (43). Drawing from these previous studies, we next analyzed whether SHP-1 associated with the tyrosine kinase Syk, the p85 adapter molecule of PtdIns 3-kinase, and the Ras GAP-binding protein p62dok during Fc{gamma}RIIa signaling. Thus, THP-1 cells were activated by clustering Fc{gamma}RIIa for various time points. SHP-1 was immunoprecipitated from resting and activated THP-1 cells and analyzed by Western blotting for the presence of co-precipitating Syk (Fig. 5A), p85 (Fig. 5B), and p62dok (Fig. 5C). As seen in the figure, SHP-1 associated with the above molecules in an activation-dependent manner. The membranes were reprobed with anti-SHP-1 antibody to ensure equal loading in all lanes. To further analyze whether active SHP-1 is associated with Syk, p85, and p62dok, phosphatase assays were performed on the respective immunoprecipitates from resting and activated THP-1 cells. Consistent with association of SHP-1 protein, results indicated that phosphatase activity was present in Syk, p85, and p62dok immunoprecipitates (Fig. 5D). In control experiments, no association of SHP-1 phosphatase activity was observed in Erk immunoprecipitates from activated THP-1 cells (data not shown). Taken together these data suggest that SHP-1 may dephosphorylate the above molecules to down-regulate activation events induced by Fc{gamma}RIIa clustering.



View larger version (33K):
[in this window]
[in a new window]
  		FIG. 5.
SHP-1 associates with Syk, p85, and p62dok upon Fc{gamma}RIIa clustering. THP-1 cells were activated by clustering Fc{gamma}RIIa for the time points indicated in the figure. SHP-1 was immunoprecipitated from resting and activated cells, and analyzed for association with Syk (A), p62dok (B), and p85 (C) (upper panels). The membranes were reprobed with anti-SHP-1 antibody to ensure equal loading (lower panels). The last lane is a control immunoprecipitate with normal rabbit IgG. D, THP-1 cells were activated for 7 min by clustering Fc{gamma}RIIa. Cell lysates from resting and activated cells were subjected to immunoprecipitation with antibodies to Syk, p85, and p62dok. The immunoprecipitates were assayed for the presence of phosphatase activity using a phosphopeptide as substrate. Phosphatase activity was measured as release of free phosphate. Values plotted represent picomole of phosphate release in each of the immunoprecipitates from activated cells after subtracting the values obtained from resting cells. Data are representative of three independent experiments.

 

SHP-1 Down-regulates Fc{gamma}RIIa-mediated Function—In recent reports we, and others, have demonstrated that Fc{gamma}RIIa clustering results in the activation of NF{kappa}B-dependent gene transcription (19, 21, 44). These activation events are subject to regulation by the inositol phosphatases SHIP-1 and SHIP-2, presumably as a result of the consumption of the lipid products of PtdIns 3-kinase and the downstream signaling thereof. Our present studies demonstrate that SHP-1 associates with the p85 subunit of PtdIns 3-kinase, suggesting that SHP-1 may modulate PtdIns 3-kinase activity. Therefore, we next asked whether SHP-1 also played a role in modulating NF{kappa}B-dependent gene transcription initiated by Fc{gamma}RIIa clustering. In these experiments we used wild-type and catalytically inactive (D419A) SHP-1 constructs, which we first expressed in COS-7 fibroblasts by transient transfection and analyzed for SHP-1 protein expression and enzyme activity. The results shown in Fig. 6B demonstrate that both wild-type and D419A SHP-1 are expressed efficiently from these plasmids. COS-7 fibroblasts do not express any endogenous SHP-1 as is seen from the absence of SHP-1 in the mock-transfected cells (lane 1). Shown in Fig. 6B, lower panel, is the phosphatase activity of these two SHP-1 proteins expressed in COS-7 cells.



View larger version (13K):
[in this window]
[in a new window]
  		FIG. 6.
SHP-1 negatively regulates NF{kappa}B-dependent gene transcription in THP-1 cells in response to Fc{gamma}RIIa clustering. A, THP-1 cells were transfected with plasmids encoding the NF{kappa}B binding element coupled to a luciferase gene (NF{kappa}B-luc), along with wild-type or D419A SHP-1. Transfectants were harvested 24 h later, activated by clustering Fc{gamma}RIIa for 5 h, and analyzed for luciferase activity. Results from three experiments are shown as mean ± S.D. of percent increase of luciferase activity in the activated samples over that in resting samples. B, COS-7 cells were transfected either with empty vector or plasmids encoding the wild-type SHP-1 or D419A SHP-1. Whole cell lysates were analyzed by Western blotting for the expression of the transfected SHP-1 (upper panel). SHP-1 was immunoprecipitated from the transfected cells and assessed for phosphatase activity (lower panel).

 

Having ensured that we could achieve appropriate protein expression from these constructs, we then transiently transfected THP-1 cells with plasmids encoding the NF{kappa}B binding element coupled to a luciferase gene (NF{kappa}B-luc) either alone or with an excess of wild-type SHP-1 or D419A SHP-1. The cells were harvested 24 h post-transfection, activated by clustering Fc{gamma}RIIa, and NF{kappa}B-dependent luciferase expression was assessed in a luciferase enzyme assay. Results from three independent experiments are shown in Fig. 6A. Overexpression of wild-type SHP-1 completely abrogated NF{kappa}B-dependent luciferase induction. In contrast, overexpression of the catalytically inactive D419A SHP-1 resulted in enhanced luciferase induction. These data demonstrate that SHP-1 negatively regulates Fc{gamma}RIIa-mediated biological outcomes in human myeloid cells.


   DISCUSSION
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
REFERENCES
 
The human-specific Fc{gamma}RIIa is a low affinity IgG receptor that has several unique features to it. In addition to being the most widely expressed IgG receptor, it also contains an unusually lengthy ITAM in its cytoplasmic domain. Mutational analyses of the cytoplasmic domain of Fc{gamma}RIIa have identified specific amino acid motifs that are important for the phagocytic process. For example, mutation of either of the two tyrosine residues within the ITAM of Fc{gamma}RIIa have been reported to severely abrogate intracellular calcium mobilization and phagocytosis (36, 45). An additional tyrosine residue located NH2-terminal to the ITAM also becomes phosphorylated upon receptor clustering and plays a role in Fc{gamma}RIIa-mediated activation (45). More recent studies have identified an LTL motif in the cytoplasmic domain of Fc{gamma}RIIa that is involved in the formation of phagolysosomes (46, 47). Thus the cytoplasmic domain of Fc{gamma}RIIa is made up of a complex set of signaling motifs that are not yet fully explored.

Once Fc{gamma}RIIa receptors are clustered the Src family of tyrosine kinases phosphorylate tyrosine residues in the cytoplasmic domain of Fc{gamma}RIIa (6). Phosphorylation of the ITAM promotes recruitment and activation of Syk, followed by the phosphorylation of multiple cytosolic signaling proteins. Unlike its T cell homolog ZAP-70 that requires both of its tandem SH2 domains to be engaged by phosphorylated ITAMs to be activated, single SH2 domain engagement is sufficient for Syk activation (48). Accordingly, the results shown in Fig. 3 demonstrate that the COOH-terminal ITAM tyrosine of Fc{gamma}RIIa is necessary and sufficient for Syk association. Interestingly, there was constitutive Syk association with Y252F Fc{gamma}RIIa, at a time when no tyrosine phosphorylation of the receptor was detectable (Fig. 4B). These results suggest that perhaps mutation of tyrosine 252 might lead to a non-SH2-dependent association of Syk with Y252F Fc{gamma}RIIa. Additional studies are needed to define the nature of this novel interaction.

Recent studies have revealed that Fc{gamma}RIIa clustering not only initiates activating events, but it also induces negative regulatory events such that the resultant biologic outcome is tempered. Thus, Fc{gamma}RIIa recruits the inositol phosphatases SHIP-1 and SHIP-2 to modulate signaling events (19–21). In a transfected COS-7 fibroblast model the protein-tyrosine phosphatase SHP-1 has also been shown to regulate Fc{gamma}RIIa-mediated phagocytosis (22). Our current studies extend these latter findings to demonstrate that in myeloid cells SHP-1 translocates to the membrane, associates with the phosphorylated NH2-terminal ITAM tyrosine of Fc{gamma}RIIa, and regulates Fc{gamma}RIIa-mediated signaling. Together, these observations suggest that signal transduction from Fc{gamma}RIIa is internally regulated by both positive and negative signaling enzymes.

SHP-1 was initially thought to be the effector molecule of Fc{gamma}RIIb-mediated inhibition (49). However, later studies using chimeric Fc{gamma}RIIb receptors and SHP-1-deficient cells demonstrated that SHP-1 is not required for Fc{gamma}RIIb function (50, 51), but that SHP-1 works in concert with other ITIM-bearing receptors such as the KIRs, gp49B, PIR-B etc. (52), to mediate its inhibitory function. Our current observations of SHP-1 association with Fc{gamma}RIIa ITAM are novel, and are consistent with earlier findings that SHP-1 association with immune receptors occurs in the absence of involvement of the ITIM-bearing Fc{gamma}RIIb (53).

Activation of SHP-1 enzyme requires the engagement of its NH2-terminal SH2 domain with phosphotyrosines to relieve the intramolecular constraint placed on the phosphatase domain (26). Consistent with this notion, our results suggest that the engagement of SHP-1 by the NH2-terminal ITAM tyrosine of Fc{gamma}RIIa leads to the activation of SHP-1. Other studies have reported a secondary mechanism of SHP-1 activation involving phosphorylation of SHP-1 on its COOH-terminal located tyrosine residues (29). In our experiments, although tyrosine phosphorylation of SHP-1 was detectable after Fc{gamma}RIIa clustering (Fig. 1), the level of phosphorylation is weak suggesting that it is likely that the primary mechanism of SHP-1 activation is mediated by its association with Fc{gamma}RIIa. Additional studies are required to assess whether the low level phosphorylation of SHP-1 contributes to activation of the enzyme.

The identification of specific substrates of SHP-1 has been aided by the use of substrate-trapping mutant forms of SHP-1 and the SHP-1-deficient motheaten animals. Consistent with earlier observations in other cell systems, we have observed association of SHP-1 with Syk, p85, and p62dok. These findings suggest that the above molecules may be dephosphorylated by SHP-1 resulting in down-regulation of the related signaling pathways. In accordance with this notion, our data indicate that SHP-1 down-regulates NF{kappa}B-dependent gene transcription in myeloid cells stimulated by clustering Fc{gamma}RIIa. NF{kappa}B activation has been shown to be important for Fc{gamma}R-induced transcription of inflammatory cytokine genes such as interleukin-1, tumor necrosis factor-{alpha}, and interleukin-8 (54). Thus the current study establishes a role for SHP-1 in modulating the production of inflammatory cytokines during immune complex clearance.


   FOOTNOTES
 
* This work was supported in part by National Institutes of Health Grants P30 CA16058, P01 CA095426 [GenBank] , HL63800, HL6176, and HL70294. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Back

{ddagger} Fellow of the Leukemia and Lymphoma Society. To whom correspondence should be addressed: Rm. 405B HLRI, 473 W. 12th Ave., Columbus, OH 43210. Tel.: 614-247-6768; Fax: 614-688-4662; E-mail: tridandapani.2{at}osu.edu.

1 The abbreviations used are: ITAM, immunoreceptor tyrosine-based activation motif; ITIM, immunoreceptor tyrosine-based inhibition motif; PtdIns, phosphatidylinositol; EGFP, enhanced green fluorescent protein; SH2, Src homology domain 2. Back


   ACKNOWLEDGMENTS
 
We thank Mark Kotur and Alan Bakaletz for assistance with confocal microscopy and J. Parker-Barnes for assistance with GFP-SHP.1 constructs.



   REFERENCES
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Aderem, A., and Underhill, D. M. (1999) Annu. Rev. Immunol. 17, 593–623
  2. Daeron, M. (1997) Annu. Rev. Immunol. 15, 203–234
  3. Van Den Herik-Oudijk, I. E., Westerdaal, N. A. C., Henriquez, N. V., Capel, P. J. A., and van de Winkel, J. G. J. (1994) J. Immunol. 152, 574–584
  4. Van Den Herik-Oudijk, I. E., Capel, P. J., Van der Bruggen, T., and van de Winkel, J. G. (1995) Blood 85, 2202–2211
  5. Ghazizadeh, S., Bolen, J. B., and Fleit, H. B. (1994) J. Biol. Chem. 269, 8878–8884
  6. Cooney, D. S., Phee, H., Jacob, A., and Coggeshall, K. M. (2001) J. Immunol. 167, 844–854
  7. Chacko, G. W., Brandt, J. T., Coggeshall, K. M., and Anderson, C. L. (1996) J. Bio. Chem. 271, 10775–10781
  8. Ghazizadeh, S., Bolen, J. B., and Fleit, H. B. (1995) Biochem. J. 305, 669–674
  9. Kiener, P. A., Rankin, B. M., Burkhardt, A. L., Schieven, G. L., Gilliland, L. K., Rowley, R. B., Bolen, J. B., and Ledbetter, J. A. (1993) J. Biol. Chem. 268, 24442–24448
  10. Krugmann, S., and Welch, H. (1998) Curr. Biol. 8, R828
  11. Crowley, M. T., Costello, P. S., Fitzer-Attas, C. J., Turner, M., Meng, F., Lowell, C., Tybuleewicz, V. L. J., and DeFranco, A. L. (1997) J. Exp. Med. 186, 1027–1039
  12. Cox, D., Chang, P., Kurosaki, T., and Greenberg, S. (1996) J. Biol. Chem. 271, 16597–16602
  13. Cox, D., Tseng, C. C., Bjekic, G., and Greenberg, S. (1999) J. Biol. Chem. 274, 1240–1247
  14. Lowry, M. B., Duchemin, A.-M., Coggeshall, K. M., Robinson, J. M., and Anderson, C. L. (1998) J. Biol. Chem. 273, 24513–24520
  15. Clynes, R., Maizes, J. S., Guinamard, R., Ono, M., Takai, T., and Ravetch, J. V. (1999) J. Exp. Med. 189, 179–185
  16. Tridandapani, S., Siefker, K., Teillaud, J.-L., Carter, J. O., Wewers, M. D., and Anderson, C. L. (2002) J. Biol. Chem. 277, 5082–5089
  17. Pricop, L., Redecha, P., Teillaud, J.-L., Frey, J., Fridman, W. H., Fridman, C. S., and Salmon, J. E. (2001) J. Immunol. 166, 531–537
  18. Cox, D., Dale, B. M., Kishiwada, M., Helgason, C. D., and Greenberg, S. (2001) J. Exp. Med. 193, 61–71
  19. Tridandapani, S., Wang, Y., Marsh, C. B., and Anderson, C. L. (2000) J. Immunol. 169, 4370–4378
  20. Nakamura, K., Malykhin, A., and Coggeshall, K. M. (2002) Blood 100, 3374–3382
  21. Pengal, R. A., Ganesan, L. P., Fang, H., Marsh, C. B., Anderson, C. L., and Tridandapani, S. (2003) J. Biol. Chem. 278, 22657–22663
  22. Kant, A. M., De, P., Peng, X., Yi, T., Rawlings, D. J., Kim, J. S., and Durden, D. L. (2002) Blood 100, 1852–1859
  23. Galandrini, R., Tassi, I., Morrone, S., Lanfrancone, L., Pelicci, P., Piccoli, M., Frati, L., and Santoni, A. (2001) Eur. J. Immunol. 31, 2016–2025
  24. Zhang, J., Somani, A. K., and Siminovitch, K. A. (2000) Immunology 12, 361–378
  25. Neel, B. G., and Tonks, N. K. (1997) Curr. Opin. Cell Biol. 9, 193–204
  26. Yang, J., Liu, L., He, D., Song, X., Liang, X., Zhao, Z. J., and Zhou, G. W. (2003) J. Biol. Chem. 278, 6516–6520
  27. Pei, D., Wang, J., and Walsh, C. T. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 1141–1145
  28. Pei, D., Lorenz, U., Klingmuller, U., Neel, B. G., and Walsh, C. T. (1994) Biochemistry 33, 15483–15493
  29. Zhang, Z., Shen, k., Lu, W., and Cole, P. A. (2002) J. Biol. Chem. 278, 4668–4674
  30. Shultz, L. D., Schweitzer, P. A., Rajan, T. V., Yi, T., Ihle, J. N., Matthews, R. J., Thomas, M. L., and Beier, D. R. (1993) Cell 73, 1445–1454
  31. Shultz, L. D., and Green, M. C. (1976) J. Immunol. 116, 936–943
  32. Green, M. C., and Shultz, L. D. (1975) J. Hered. 66, 250–258
  33. Dustin, L. B., Plas, D. R., Wong, J., Hu, Y. T., Soto, C., Chan, A. C., and Thomas, M. L. (1999) J. Immunol. 162, 2717–2724
  34. Cuevas, B., Lu, Y., Watt, S., Kumar, R., Zhang, J., Siminovitch, K. A., and Mills, G. B. (1999) J. Biol. Chem. 274, 27583–27589
  35. Berg, K. L., Siminovitch, K. A., and Stanley, E. R. (1999) J. Biol. Chem. 274, 35855–35865
  36. Edberg, J. C., Lin, C. T., Lau, D., Unkeless, J. C., and Kimberly, R. P. (1995) J. Biol. Chem. 270, 22301–22307
  37. Kon-Kozlowski, M., Pani, G., Pawson, T., and Siminovitch, K. A. (1996) J. Biol. Chem. 271, 3856–3862
  38. Xie, Z. H., Zhang, J., and Siraganian, R. P. (2000) J. Immunol. 164, 1521–1528
  39. Tridandapani, S., Lyden, T. W., Smith, J. L., Carter, J. E., Coggeshall, K. M., and Anderson, C. L. (2000) J. Biol. Chem. 275, 20480–20487
  40. Kim, M. K., Pan, X. Q., Huang, Z. Y., Hunter, S., Hwang, P. H., Indik, Z. K., and Schreiber, A. D. (2001) Clin. Immunol. 98, 125–132
  41. Gibbins, J. M., Briddon, S., Shutes, A., Van Vugt, M. J., De Winkel, J. G., Saito, T., and Watson, S. P. (1998) J. Biol. Chem. 273, 34437–34443
  42. Vely, F., Gruel, N., Moncuit, J., Cochet, O., Rouard, H., Dare, S., Galon, J., Sautes, C., Fridman, W. H., and Teillaud, J.-L. (1997) Hybridoma 16, 519–528
  43. Veillette, A., Latour, S., and Davidson, D. (2002) Annu. Rev. Immunol. 20, 669–707
  44. Sánchez-Mejorada, G., and Rosales, C. (1998) J. Leukocyte Biol. 63, 521–533
  45. Mitchell, M. A., Huang, M. M., Chien, P., Indik, Z. K., Pan, X. Q., and Schreiber, A. D. (1994) Blood 84, 1753–1759
  46. Worth, R. G., Mayo-Bond, L., Kim, M. K., van de Winkel, J. G., Todd, R. F., III, Petty, H. R., and Schreiber, A. D. (2001) Blood 98, 3429–3434
  47. Worth, R. G., Kim, M. K., Kindzelskii, A. L., Petty, H. R., and Schreiber, A. D. (2003) Proc. Natl. Acad. Sci. U. S. A. 100, 4533–4538
  48. Futterer, K., Wong, J., Grucza, R. A., Chan, A. C., and Waksman, G. (1998) J. Mol. Biol. 281, 523–537
  49. D'Ambrosio, D., Hippen, K. L., Minskoff, S. A., Mellman, I., Pani, G., Siminovitch, K. A., and Cambier, J. C. (1995) Science 268, 293–296
  50. Ono, M., Okada, H., Bolland, S., Yanagi, S., Kurosaki, T., and Ravetch, J. V. (1997) Cell 90, 293–301
  51. Nadler, M. J. S., Chen, B., Anderson, J. S., Wortis, H. H., and Neel, B. G. (1997) J. Biol. Chem. 272, 20038–20043
  52. Pani, G., and Siminovitch, K. A. (1997) Clin. Immunol. Immunopathol. 84, 1–16
  53. Phee, H., Rodgers, W., and Coggeshall, K. M. (2001) Mol. Cell. Biol. 21, 8615–8625
  54. Sanchez-Mejorada, G., and Rosales, C. (1998) J. Biol. Chem. 273, 27610–27619

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 J. Immunol.Home page
L. Marois, M. Vaillancourt, S. Marois, S. Proulx, G. Pare, E. Rollet-Labelle, and P. H. Naccache
The Ubiquitin Ligase c-Cbl Down-Regulates Fc{gamma}RIIa Activation in Human Neutrophils
J. Immunol., February 15, 2009; 182(4): 2374 - 2384.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
C. Canetti, C. H. Serezani, R. G. Atrasz, E. S. White, D. M. Aronoff, and M. Peters-Golden
Activation of Phosphatase and Tensin Homolog on Chromosome 10 Mediates the Inhibition of Fc{gamma}R Phagocytosis by Prostaglandin E2 in Alveolar Macrophages
J. Immunol., December 15, 2007; 179(12): 8350 - 8356.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
J. P. Butchar, M. V. S. Rajaram, L. P. Ganesan, K. V. L. Parsa, C. D. Clay, L. S. Schlesinger, and S. Tridandapani
Francisella tularensis Induces IL-23 Production in Human Monocytes
J. Immunol., April 1, 2007; 178(7): 4445 - 4454.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. V. S. Rajaram, L. P. Ganesan, K. V. L. Parsa, J. P. Butchar, J. S. Gunn, and S. Tridandapani
Akt/Protein Kinase B Modulates Macrophage Inflammatory Response to Francisella Infection and Confers a Survival Advantage in Mice
J. Immunol., November 1, 2006; 177(9): 6317 - 6324.
[Abstract] [Full Text] [PDF]

Home page
 Sci SignalHome page
J. A. Hamerman and L. L. Lanier
Inhibition of Immune Responses by ITAM-Bearing Receptors
Sci. Signal., January 31, 2006; 2006(320): re1 - re1.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. Ai, A. Maturu, W. Johnson, Y. Wang, C. B. Marsh, and S. Tridandapani
The inositol phosphatase SHIP-2 down-regulates Fc{gamma}R-mediated phagocytosis in murine macrophages independently of SHIP-1
Blood, January 15, 2006; 107(2): 813 - 820.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
J. A. Swanson and A. D. Hoppe
The coordination of signaling during Fc receptor-mediated phagocytosis
J. Leukoc. Biol., December 1, 2004; 76(6): 1093 - 1103.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
X. Cao, G. Wei, H. Fang, J. Guo, M. Weinstein, C. B. Marsh, M. C. Ostrowski, and S. Tridandapani
The Inositol 3-Phosphatase PTEN Negatively Regulates Fc{gamma} Receptor Signaling, but Supports Toll-Like Receptor 4 Signaling in Murine Peritoneal Macrophages
J. Immunol., April 15, 2004; 172(8): 4851 - 4857.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
278/37/35710    most recent
M305078200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ganesan, L. P.
Right arrow Articles by Tridandapani, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ganesan, L. P.
Right arrow Articles by Tridandapani, S.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2003 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement